Table 1:

Demographics, cognitive scores, AD biomarker characteristic, and number of flortaucipir PET scans within study cohorts. Baseline refers to first flortaucipir PET observation time point.

	ADNI (N=326)		AVID-05 (N=161)		HABS (N=126)
Variables	Mean (SD)	Range	Mean (SD)	Range	Mean (SD)	Range
Age (years; baseline)	74.2 (7.3)	[55.7,92.2]	71.0 (9.7)	[50.0,95.0]	75.7 (6.1)	[64.8,90.0]
Education	16.4 (2.7)	[8,20]	15.5 (2.2)	[8,18]	16.0 (3.1)	[8,20]
Duration of flortaucipir PET follow-up (years)	2.2 (1.1)	[0.65,5.9]	1.4 (0.3)	[0.6, 1.9]	2.4 (0.9)	[1.2,5.6]
% Female (N)	48% (157)		49% (79)		56% (70)
% Black or African American (N)	5.6% (18)		N/A		13.6% (17)
% Asian (N)	0.9% (3)		N/A		0.8% (1)
% Hispanic or Latinx (N)	5.6% (18)		N/A		0% (0)
% CU (N) (baseline)	52% (171)		32% (51)		100% (126)
% MCI (N) (baseline)	34% (111)		48% (77)		0% (0)
% Dementia (N) (baseline)	13% (44)		20% (33)		0% (0)
% w/ 2-timepoint flortaucipir PET scans	56% (184)		20% (32)		86% (108)
% w/ 3-timepoint flortaucipir PET scans	44% (142)		80% (129)		14% (18)

APOE: apolipoprotein E gene; MMSE: Mini-Mental State Examination; PET: positron emission tomography